Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04264312
Other study ID # BJCDCWJ202001
Secondary ID
Status Completed
Phase
First received
Last updated
Start date July 28, 2017
Est. completion date January 10, 2020

Study information

Verified date February 2020
Source Centers for Disease Control and Prevention, China
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Through two-stage stratified cluster sampling, investigators studied the antiviral treatment rate and the main factors affecting the antiviral treatment in community chronic HBV infection-related liver disease population.


Description:

Hepatitis B virus (HBV) infection is a major public health problem worldwide. China has the world's largest burden of HBV infection and will be a major contributor towards the global elimination of hepatitis B disease by 2030. While, the antiviral treatment rate and the main factors affecting the antiviral treatment in community chronic HBV infections is still unknown. In response to the above situation, Sampling applied a two-stage stratified cluster sampling design in 16 Districts and 331 Townships. Investigators wanted to know the one who is eligible for treated criteria based on community in 25 and over years old in Beijing.


Recruitment information / eligibility

Status Completed
Enrollment 76220
Est. completion date January 10, 2020
Est. primary completion date September 28, 2019
Accepts healthy volunteers No
Gender All
Age group 25 Years and older
Eligibility Inclusion Criteria:

- older than 25 years old;

- Residents with medical insurance coverage lived in Beijing more than 6 months .

Exclusion Criteria:

- Persons with pacemakers;

- Pregnant women;

- Persons with ascites;

- The one whose wound was not cured at the right upper abdomen

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
China Changping District Center for Disease Prevention and Control Beijing
China Chaoyang District Center for Disease Control and Prevention Beijing Beijing
China Daxing District Center for Disease Prevention and Control Beijing Beijing
China Dongcheng District Center for Disease Control and Prevention Beijing Beijing
China FangShan District Center for Disease Prevention and Control Beijing
China Fengtai District Center for Disease Control and Prevention Beijing Beijing
China Haidian District Center for Disease Prevention and Control Beijing
China Huairou District Center for Disease Prevention and Control Beijing Beijing
China Miyun District Center for Disease Prevention and Control Beijing
China Tongzhou District Center for Disease Prevention and Control Beijing
China Xicheng District Center for Disease Prevention and Control Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Wu Jiang

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary HBsAg positive rate Complete HBsAg tests for more than 60,000 people over the age of 25 in Beijing Baseline
Primary Average rate of chronic hepatitis B accepting antiviral treatment The one who is eligible for HBV treated criteria based on community in 25 and over years old in Beijing. Baseline
See also
  Status Clinical Trial Phase
Completed NCT01182311 - Duration of Long-term Immunity After Hepatitis B Virus Immunization
Completed NCT04971928 - Phase 1 Study of GSK3228836 Pharmacokinetics in Participants With Hepatic Impairment Phase 1
Completed NCT03285620 - A Study of AL-034 to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses in Healthy Participants Phase 1
Completed NCT01884415 - Phase III, Study to Evaluate the Efficacy of Two Different HBV Vaccination Schemes in Patients With Hepatic Cirrhosis Phase 3
Recruiting NCT05404919 - Utilization of Hepatitis B Virus NAT+ Donors for Hepatitis B Vaccinated Lung Transplant Candidates Phase 2
Completed NCT02153320 - Study to Evaluate the Persistence of the Cellular and Humoral Immune Response Following Vaccinations With GlaxoSmithKline (GSK) Biologicals' Candidate Vaccines Containing HBsAg and Different Adjuvants in Healthy Adult Volunteers Phase 1
Completed NCT00352963 - Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age). Phase 3
Completed NCT03567382 - Arresting Vertical Transmission of Hepatitis B Virus Phase 4
Not yet recruiting NCT04056728 - A Phase IV Study to Assess the Safety of EupentaTM Inj Phase 4
Not yet recruiting NCT03604016 - Study to Assess Efficacy of Besifovir and L-carnitine in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver Phase 4
Completed NCT00753649 - Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants Phase 4
Recruiting NCT03027258 - Point-of-Delivery Prenatal Test Results Through mHealth to Improve Birth Outcome N/A
Terminated NCT02604199 - A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection Phase 2
Completed NCT02540538 - Safety and Immunogenicity of HBAI20 Hepatitis B Vaccine in Naive Adults and Non-responders Phase 1
Completed NCT02421666 - A Comparative Trial of Improving Care for Underserved Asian Americans Infected With HBV N/A
Completed NCT02169674 - Hepatitis B Booster Study in Adolescence Phase 4
Completed NCT01917357 - A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject Phase 3
Completed NCT01732354 - Study for Consolidation Period of Chronic Hepatitis B
Completed NCT01368497 - Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic Hepatitis B Virus (HBV) Infection Phase 3
Recruiting NCT01462981 - Cohort of Hepatitis B Research of Amsterdam N/A